1 to 2 of 2 literature results

• Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

  Notch signaling is an area of great interest in oncology. RO4929097 is a potent and selective inhibitor of gamma-secretase, producing inhibitory activ…

  Authors: Leopoldo Luistro, Wei He, Melissa Smith, Kathryn Packman, Maria Vilenchik, Daisy Carvajal, John Roberts, James Cai, Windy Berkofsky-Fessler, Holly Hilton,…

  Source: Cancer research. 2009 Oct 1

  View Full Text

• In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.

  The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of distinct cyclin-dependen…

  Authors: Wanda DePinto, Xin-Jie Chu, Xuefeng Yin, Melissa Smith, Kathryn Packman, Petra Goelzer, Allen Lovey, Yingsi Chen, Hong Qian, Rachid Hamid,…

  Source: Molecular cancer therapeutics. 2006 Nov

  View Full Text